[SCHEDULE 13G/A] Verona Pharma plc SEC Filing
Perceptive Advisors, Joseph Edelman and Perceptive Life Sciences Master Fund report a 6.4% stake in Verona Pharma plc. The filing shows the Master Fund directly holds 5,507,591 American Depositary Shares (ADSs), equal to 44,060,728 ordinary shares because each ADS represents eight ordinary shares. Perceptive Advisors (investment manager) and Joseph Edelman (managing member) report shared voting and dispositive power over the 5,507,591 ADSs and no sole voting or dispositive power. The ownership percentage is calculated using 689,536,966 outstanding ordinary shares (86,192,121 ADSs) as reported by the issuer.
Perceptive Advisors, Joseph Edelman e Perceptive Life Sciences Master Fund comunicano una partecipazione del 6,4% in Verona Pharma plc. La dichiarazione indica che il Master Fund detiene direttamente 5.507.591 American Depositary Shares (ADS), corrispondenti a 44.060.728 azioni ordinarie, poich茅 ogni ADS rappresenta otto azioni ordinarie. Perceptive Advisors (gestore degli investimenti) e Joseph Edelman (membro amministrativo) dichiarano poteri congiunti di voto e disposizione sulle 5.507.591 ADS e nessun potere di voto o di disposizione esclusivo. La percentuale di propriet脿 猫 calcolata su 689.536.966 azioni ordinarie in circolazione (86.192.121 ADS) come riportato dall'emittente.
Perceptive Advisors, Joseph Edelman y Perceptive Life Sciences Master Fund informan una participaci贸n del 6,4% en Verona Pharma plc. El documento muestra que el Master Fund posee directamente 5.507.591 American Depositary Shares (ADS), equivalentes a 44.060.728 acciones ordinarias, ya que cada ADS representa ocho acciones ordinarias. Perceptive Advisors (gestor de inversiones) y Joseph Edelman (miembro directivo) declaran poder conjunto de voto y disposici贸n sobre las 5.507.591 ADS y ning煤n poder de voto o disposici贸n exclusivo. El porcentaje de propiedad se calcula sobre 689.536.966 acciones ordinarias en circulaci贸n (86.192.121 ADS) seg煤n lo informado por el emisor.
Perceptive Advisors, Joseph Edelman 氚� Perceptive Life Sciences Master Fund臧� Verona Pharma plc 歆�攵� 6.4%毳� 鞁犼碃頄堨姷雼堧嫟. 鞝滌稖靹滊鞐� 霐半ゴ氅� Master Fund電� 5,507,591臧滌潣 American Depositary Shares(ADS)毳� 歆侅爲 氤挫湢頃橁碃 鞛堨溂氅�, 臧� ADS臧� 氤错喌欤� 8欤茧ゼ 雮橅儉雮措瘈搿� 鞚措姅 氤错喌欤� 44,060,728欤检棎 頃措嫻頃╇媹雼�. Perceptive Advisors(韴瀽毵る媹鞝�)鞕� Joseph Edelman(甏�毽� 氅る矂)鞚� 5,507,591 ADS鞐� 雽�頃� 瓿惦彊 鞚橁舶甓� 氚� 觳橂秳甓岇潉 氤挫湢頃滊嫟瓿� 氤搓碃頄堨溂氅�, 雼弲 鞚橁舶甓� 霕愲姅 觳橂秳甓岇潃 鞐嗠嫟瓿� 氇呾嫓頄堨姷雼堧嫟. 靻岇湢 牍勳湪鞚� 氚滍枆靷皜 氤搓碃頃� 鞙犿喌 氤错喌欤� 689,536,966欤�(86,192,121 ADS)毳� 旮办鞙茧 瓿勳偘霅橃棃鞀惦媹雼�.
Perceptive Advisors, Joseph Edelman et Perceptive Life Sciences Master Fund d茅clarent une participation de 6,4 % dans Verona Pharma plc. Le d茅p么t indique que le Master Fund d茅tient directement 5 507 591 American Depositary Shares (ADS), soit l'茅quivalent de 44 060 728 actions ordinaires, car chaque ADS repr茅sente huit actions ordinaires. Perceptive Advisors (gestionnaire d'investissement) et Joseph Edelman (membre dirigeant) d茅clarent exercer conjointement le pouvoir de vote et de disposition sur les 5 507 591 ADS et ne poss茅der aucun pouvoir de vote ou de disposition exclusif. Le pourcentage de participation est calcul茅 sur la base de 689 536 966 actions ordinaires en circulation (86 192 121 ADS), tel que communiqu茅 par l'茅metteur.
Perceptive Advisors, Joseph Edelman und Perceptive Life Sciences Master Fund melden einen Anteil von 6,4 % an Verona Pharma plc. Die Meldung weist aus, dass der Master Fund direkt 5.507.591 American Depositary Shares (ADS) h盲lt, was 44.060.728 Stammaktien entspricht, da jede ADS acht Stammaktien repr盲sentiert. Perceptive Advisors (Investmentmanager) und Joseph Edelman (gesch盲ftsf眉hrendes Mitglied) geben an, 眉ber die 5.507.591 ADS gemeinschaftliche Stimm- und Verf眉gungsrechte zu verf眉gen und keine alleinigen Stimm- oder Verf眉gungsrechte zu haben. Der Eigentumsanteil wurde auf Basis von 689.536.966 ausstehenden Stammaktien (86.192.121 ADS) berechnet, wie vom Emittenten berichtet.
- Disclosure of a >5% passive stake (6.4%) in Verona Pharma provides transparency to the market
- Detailed ADS conversion included: 5,507,591 ADSs equal 44,060,728 ordinary shares (1 ADS = 8 ordinary shares)
- Clear identification of reporting chain: Master Fund holdings, Perceptive Advisors as manager, and Joseph Edelman as managing member
- None.
Insights
TL;DR: A hedge fund group reports a notable 6.4% stake via shared voting power, a meaningful passive stake above 5%.
The filing confirms Perceptive Life Sciences Master Fund holds 5,507,591 ADSs (44,060,728 ordinary shares) representing 6.4% of Verona Pharma's outstanding shares on the stated basis. Ownership is reported as shared voting and dispositive power, not sole control, and Perceptive Advisors acts as investment manager with Joseph Edelman as managing member. For investors, this is a clear disclosure of a >5% passive position required under Schedule 13G, indicating significant ownership without an expressed intent to change control.
TL;DR: Reporting shows coordinated ownership and shared authority, but no claim of control or intent to influence governance.
The document contains the required certifications that the securities are not held to change or influence issuer control. The reporting persons classify as an investment adviser, individual, and a Cayman fund, respectively. Signatures by Joseph Edelman appear for all reporting entities, reinforcing the linkage between the manager and the fund. This filing primarily provides transparency on ownership concentration and related voting/dispositive arrangements.
Perceptive Advisors, Joseph Edelman e Perceptive Life Sciences Master Fund comunicano una partecipazione del 6,4% in Verona Pharma plc. La dichiarazione indica che il Master Fund detiene direttamente 5.507.591 American Depositary Shares (ADS), corrispondenti a 44.060.728 azioni ordinarie, poich茅 ogni ADS rappresenta otto azioni ordinarie. Perceptive Advisors (gestore degli investimenti) e Joseph Edelman (membro amministrativo) dichiarano poteri congiunti di voto e disposizione sulle 5.507.591 ADS e nessun potere di voto o di disposizione esclusivo. La percentuale di propriet脿 猫 calcolata su 689.536.966 azioni ordinarie in circolazione (86.192.121 ADS) come riportato dall'emittente.
Perceptive Advisors, Joseph Edelman y Perceptive Life Sciences Master Fund informan una participaci贸n del 6,4% en Verona Pharma plc. El documento muestra que el Master Fund posee directamente 5.507.591 American Depositary Shares (ADS), equivalentes a 44.060.728 acciones ordinarias, ya que cada ADS representa ocho acciones ordinarias. Perceptive Advisors (gestor de inversiones) y Joseph Edelman (miembro directivo) declaran poder conjunto de voto y disposici贸n sobre las 5.507.591 ADS y ning煤n poder de voto o disposici贸n exclusivo. El porcentaje de propiedad se calcula sobre 689.536.966 acciones ordinarias en circulaci贸n (86.192.121 ADS) seg煤n lo informado por el emisor.
Perceptive Advisors, Joseph Edelman 氚� Perceptive Life Sciences Master Fund臧� Verona Pharma plc 歆�攵� 6.4%毳� 鞁犼碃頄堨姷雼堧嫟. 鞝滌稖靹滊鞐� 霐半ゴ氅� Master Fund電� 5,507,591臧滌潣 American Depositary Shares(ADS)毳� 歆侅爲 氤挫湢頃橁碃 鞛堨溂氅�, 臧� ADS臧� 氤错喌欤� 8欤茧ゼ 雮橅儉雮措瘈搿� 鞚措姅 氤错喌欤� 44,060,728欤检棎 頃措嫻頃╇媹雼�. Perceptive Advisors(韴瀽毵る媹鞝�)鞕� Joseph Edelman(甏�毽� 氅る矂)鞚� 5,507,591 ADS鞐� 雽�頃� 瓿惦彊 鞚橁舶甓� 氚� 觳橂秳甓岇潉 氤挫湢頃滊嫟瓿� 氤搓碃頄堨溂氅�, 雼弲 鞚橁舶甓� 霕愲姅 觳橂秳甓岇潃 鞐嗠嫟瓿� 氇呾嫓頄堨姷雼堧嫟. 靻岇湢 牍勳湪鞚� 氚滍枆靷皜 氤搓碃頃� 鞙犿喌 氤错喌欤� 689,536,966欤�(86,192,121 ADS)毳� 旮办鞙茧 瓿勳偘霅橃棃鞀惦媹雼�.
Perceptive Advisors, Joseph Edelman et Perceptive Life Sciences Master Fund d茅clarent une participation de 6,4 % dans Verona Pharma plc. Le d茅p么t indique que le Master Fund d茅tient directement 5 507 591 American Depositary Shares (ADS), soit l'茅quivalent de 44 060 728 actions ordinaires, car chaque ADS repr茅sente huit actions ordinaires. Perceptive Advisors (gestionnaire d'investissement) et Joseph Edelman (membre dirigeant) d茅clarent exercer conjointement le pouvoir de vote et de disposition sur les 5 507 591 ADS et ne poss茅der aucun pouvoir de vote ou de disposition exclusif. Le pourcentage de participation est calcul茅 sur la base de 689 536 966 actions ordinaires en circulation (86 192 121 ADS), tel que communiqu茅 par l'茅metteur.
Perceptive Advisors, Joseph Edelman und Perceptive Life Sciences Master Fund melden einen Anteil von 6,4 % an Verona Pharma plc. Die Meldung weist aus, dass der Master Fund direkt 5.507.591 American Depositary Shares (ADS) h盲lt, was 44.060.728 Stammaktien entspricht, da jede ADS acht Stammaktien repr盲sentiert. Perceptive Advisors (Investmentmanager) und Joseph Edelman (gesch盲ftsf眉hrendes Mitglied) geben an, 眉ber die 5.507.591 ADS gemeinschaftliche Stimm- und Verf眉gungsrechte zu verf眉gen und keine alleinigen Stimm- oder Verf眉gungsrechte zu haben. Der Eigentumsanteil wurde auf Basis von 689.536.966 ausstehenden Stammaktien (86.192.121 ADS) berechnet, wie vom Emittenten berichtet.
FAQ
How many Verona Pharma (VRNA) ADSs does Perceptive Life Sciences Master Fund hold?
What percent of Verona Pharma (VRNA) does the filing report?
Does Perceptive Advisors or Joseph Edelman have sole voting power over VRNA shares?
Where is the issuer Verona Pharma plc headquartered according to the filing?
When was this Schedule 13G/A signed and by whom?
